Mothers with diabetes are less likely to achieve successful breastfeeding. Antenatal breastmilk expression (ABE) may facilitate earlier breastfeeding, but feasibility of introducing ABE and its acceptance among Scandinavian women have previously not been investigated. This observational trial was conducted between the 1 January 2019 and the 12 March 2020 in Tromsø, Norway. We aimed to determine the feasibility of ABE in terms of practicality and acceptability among women with medically (metformin or insulin) treated diabetes. Women were invited to participate during antenatal visits from 32 weeks gestation. Participants received instruction and started ABE from gestation week 37 + 0. Participants, and their infants, were followed until 6–8 weeks after birth. We collected data on breastfeeding rates, infant hypoglycemia, transfer to the neonatal unit, and the women’s overall experience and satisfaction with antenatal breastmilk expression. Twenty-eight of 34 (82%) invited women consented to participate. All started ABE from week 37 + 0, and continued until hospital admission. No women reported any discomfort or side effects. Labor was induced at 38 weeks gestation. Twenty-four women brought harvested colostrum to the maternity ward, which was given to their infants during the first 24 h of life. Breastfeeding rates at discharge were 24/28 (86%) and 21/27 (78%) at 6–8 weeks after delivery. Seven (25%) infants were transferred to the neonatal unit; four because of hypoglycemia. Maternal satisfaction assessed 6–8 weeks after delivery revealed that all participants felt positive about the ABE, but one woman would not recommend it to other pregnant women. Implementing a structured ABE guideline for women with medically treated diabetes was feasible. The intervention was associated with high level of satisfaction among study participants. No obvious side effects were observed, and breastfeeding rates at discharge and 6–8 weeks after delivery were higher than in comparable studies. The study was registered at the research study registry at the University Hospital of North Norway ( Nr 2018/7181 ).

中文翻译：

---

妊娠期糖尿病妇女的产前母乳表达 - 一项可行性研究

患有糖尿病的母亲不太可能成功进行母乳喂养。产前母乳表达 (ABE) 可能有助于早期母乳喂养，但之前尚未研究引入 ABE 的可行性及其在斯堪的纳维亚妇女中的接受程度。该观察性试验于 2019 年 1 月 1 日至 2020 年 3 月 12 日在挪威特罗姆瑟进行。我们旨在确定 ABE 在接受药物（二甲双胍或胰岛素）治疗的糖尿病女性的实用性和可接受性方面的可行性。从妊娠 32 周开始，妇女被邀请参加产前检查。参与者接受指导并从妊娠 37 + 0 周开始 ABE。参与者及其婴儿被随访至出生后 6-8 周。我们收集了母乳喂养率、婴儿低血糖、转移到新生儿科，以及妇女对产前母乳表达的整体体验和满意度。34 名受邀女性中有 28 名 (82%) 同意参加。所有人都从第 37 + 0 周开始 ABE，并一直持续到入院。没有女性报告任何不适或副作用。在妊娠 38 周时引产。24 名妇女将收获的初乳带到产科病房，这些初乳是在婴儿出生后的前 24 小时内给予的。分娩后 6-8 周出院时的母乳喂养率为 24/28 (86%) 和 21/27 (78%)。七名 (25%) 婴儿被转移到新生儿病房；四是因为低血糖。分娩后 6-8 周评估的产妇满意度显示所有参与者都对 ABE 感到积极，但一名妇女不会将其推荐给其他孕妇。为接受药物治疗的糖尿病女性实施结构化 ABE 指南是可行的。干预与研究参与者的高满意度有关。没有观察到明显的副作用，出院时和分娩后 6-8 周的母乳喂养率高于可比研究。该研究已在北挪威大学医院的研究登记处注册 (Nr 2018/7181)。